Adjuvant therapy in primary GIST: State-of-the-art

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2776-2781

  Reichardt, P ^a   Blay, J Y ^b   Boukovinas, I ^c   Brodowicz, T ^d   Broto, J M ^e   Casali, P G ^f   Decatris, M ^g   Eriksson, M ^h   Gelderblom, H ⁱ   Kosmidis, P ^j   Le cesne, A ^k   Pousa, A L ^l   Schlemmer, M ^m   Verweij, J ⁿ   Joensuu, H ^o  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b CENTRE LÉON BÉRARD   (France)

^c THEAGENIO CANCER HOSPITAL   (Greece)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e COTMES ^*  (Spain)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Bank of Cyprus Group Oncology Centre   (Cyprus)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j HYGEIA HOSPITAL   (Greece)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^m UNIVERSITY OF MUNICH   (Germany)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

more..

Author keywords

Adjuvant; Gastrointestinal stromal tumour; GIST; Imatinib; Recommendation

Indexed keywords

EID: 84868113228     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds198     Document Type: Review

References (35)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478.
2. Tryggvason G, Gislason HG, Magnusson MK et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005; 117: 289-293.
3. Martin-Broto J, Gutierrez A, Garcia-del-Muro X et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a spanish group for sarcoma research (GEIS) study. Ann Oncol 2010; 21: 1552-1557.
4. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
5. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11: 465-475.
6. Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005; 103: 821-829.
7. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625.
8. Blesius A, Cassier PA, Ray-Coquard IL et al. Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French sarcoma group randomized phase III trial. ASCO Meeting Abstr 2011; 29: 10048.
9. Nilsson B, Sjolund K, Kindblom LG et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96: 1656-1658.
10. Kim KM, Kang DW, Moon WS et al. Gastrointestinal stromal tumors in Koreans: its incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci 2005; 20: 977-984.
11. Li J, Gong JF, Wu AW et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011; 37: 319-324.
12. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
13. Corless CL, Ballman KV, Antonescu C et al. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol 2010; 28: 10006; 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
14. Blackstein ME, Corless CL, Ballman KV et al. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor (GIST): North American intergroup phase III trial ACOSOG Z9001. 2010 Gastrointestinal Cancers Symposium 2010; Meeting Abstracts.
15. Joensuu H, Eriksson M, Sundby Hall K et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307(12): 1265-1272.
16. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83.
17. Rutkowski P, Bylina E, Wozniak A et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - The impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011; 37: 890-896.
18. Gold JS, Gonen M, Gutierrez A et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009; 10: 1045-1052.
19. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465.
20. Rossi S, Miceli R, Messerini L et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol 2011; 35(11): 1646-1656.
21. Joensuu H, Vehtari A, Riihimäki J et al. Risk of gastrointestinal stromal tumour recurrence after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265-274.
22. Gouveia AM, Pimenta AP, Capelinha AF et al. Surgical margin status and prognosis of gastrointestinal stromal tumor. World J Surg 2008; 32: 2375-2382.
23. Casali PG, Jost L, Reichardt P et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(Suppl 4): 64-67.
24. Hohenberger P, Ronellenfitsch U, Oladeji O et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010; 97: 1854-1859.
25. Prenen H, Cools J, Mentens N et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12: 2622-2627.
26. Le Cesne A, Ray-Coquard I, Bui B et al. Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol 2007; 25: 10005 (Meeting Abstracts).
27. Domont J, Blay J, Ray-Coquard IL et al. Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: results of the BFR14 prospective french sarcoma group randomized phase III trial. ASCO Meeting Abstr 2011; 29: 10054.
28. Demetri GD, Wang Y, Wehrle E et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27(19): 3141-3147.
29. von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 2011; 37: 291-299.
30. Bui B, Italiano A, Miranova A et al. Trough imatinib plasma levels in patients treated for advanced gastrointestinal stromal tumors evidence of large interpatient variations under treatment with standard doses. J Clin Oncol 2008; 26: 569s. abstr 10564.
31. Eechoute K, Fransson MN, De Giorgi U et al. Correlation between imatinib trough levels and clinical benefit in gastrointestinal stromal tumors (GIST): results of a prospective population pharmacokinetic study. ASCO Meeting Abstr 2011; 29: 10014.
32. Demetri GD, von Mehren M, Antonescu CR et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw 2010; 8(Suppl 2): S1-S41; quiz S42-44.
33. Joensuu H, Trent JC, Reichardt P. Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treat Rev 2011; 37: 75-88.
34. Sakurai S, Hishima T, Takazawa Y et al. Gastrointestinal stromal tumors and KITpositive mesenchymal cells in the omentum. Pathol Int 2001; 51: 524-531.
35. Goh BK, Chow PK, Kesavan SM et al. A single-institution experience with eight CD117-positive primary extragastrointestinal stromal tumors: critical appraisal and a comparison with their gastrointestinal counterparts. J Gastrointest Surg 2009; 6: 1094-1098.